http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-112016024918-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cac023d2e2874224ecbbcccbdea1fc91
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-13
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-13
filingDate 2015-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fc36d4e98b7603c171687f286477a2f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6367388bc18420ab5983d3d5607269c6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c059fdcaafde9832b7258a2d3ffc6411
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_360243056e4979f0dca54f4e10179939
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fae01a0c74a6617d2584156dba3739d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e38425629fc6a078ec2d97bfbd400fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3c25969ddd6a31dc6c6b08682ac4740
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0152971a6cb8a20d6cedfe905b29c77f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e8a810ccb8bb9347fd8eeb94f072d8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70f6b4ecbb6816232b24ccbf3abceffd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_499cc0cec8b5f5433ec53762a7df0344
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_256a39e150b56fb063362a5a6a960c3f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32913619ece2c25b8fd875aad7fc8dcd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68c26e6654573e0ad3c7a9584f8c7d16
publicationDate 2017-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber BR-112016024918-A2
titleOfInvention ? use of a drug?
abstract a drug for treating tinnitus patients, which is accompanied by sudden hearing loss, said drug including neramexane or a pharmaceutically acceptable salt thereof and characterized by the period in which patients are affected by tinnitus accompanied by sudden hearing loss, which is at least 48 months etc.
priorityDate 2014-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6433106
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419494653

Total number of triples: 28.